abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
27 juil. 2023 09h22 HE | ABVC BioPharma, Inc.
FREMONT, CA, July 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
26 juil. 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Reverse Stock Split
24 juil. 2023 12h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency
06 juil. 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, July 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
26 juin 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
20 juin 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
12 juin 2023 08h30 HE | ABVC BioPharma, Inc.
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization
06 juin 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, June 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
22 mai 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
04 mai 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...